Núñez Kelley G, Gonzalez-Rosario Janet, Thevenot Paul T, Cohen Ari J
Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA.
Multi-Organ Transplant Institute, Ochsner Clinic Foundation, New Orleans, LA ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.
Ochsner J. 2017 Spring;17(1):56-65.
Cyclin D1 is an important protein for cell cycle progression; however, functions independent of the cell cycle have been described in the liver. Cyclin D1 is also involved in DNA repair, is overexpressed in many cancers, and functions as a proto-oncogene. The lesser-known roles of Cyclin D1, specifically in hepatocytes, impact liver steatosis and hormone regulation in the liver.
A comprehensive search of PubMed was conducted using the keywords Cyclin D1, steatosis, lipogenesis, and liver transplantation. In this article, we review the results from this literature search, with a focus on the role of Cyclin D1 in hepatic lipogenesis and gluconeogenesis, as well as the impact and function of this protein in hepatic steatosis.
Cyclin D1 represses carbohydrate response element binding protein (ChREBP) and results in a decrease in transcription of fatty acid synthase (FAS) and acetyl-coenzyme A carboxylase (ACC). Cyclin D1 also inhibits peroxisome proliferator-activated receptor gamma (PPARγ) which is involved in hepatic lipogenesis. Cyclin D1 inhibits both hepatocyte nuclear factor 4 alpha (HNF4α) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α) and represses transcription of lipogenic genes FAS and liver-type pyruvate kinase (Pklr), along with the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase).
Cyclin D1 represses multiple proteins involved in both lipogenesis and gluconeogenesis in the liver. Targeting Cyclin D1 to decrease hepatic steatosis in patients with nonalcoholic fatty liver disease or alcoholic fatty liver disease may help improve patient health and the quality of the donor liver pool.
细胞周期蛋白D1是细胞周期进程中的一种重要蛋白质;然而,其在肝脏中具有独立于细胞周期的功能。细胞周期蛋白D1还参与DNA修复,在许多癌症中过表达,并作为原癌基因发挥作用。细胞周期蛋白D1鲜为人知的作用,特别是在肝细胞中的作用,会影响肝脏脂肪变性和肝脏中的激素调节。
使用关键词“细胞周期蛋白D1”“脂肪变性”“脂肪生成”和“肝移植”对PubMed进行全面检索。在本文中,我们回顾了该文献检索的结果,重点关注细胞周期蛋白D1在肝脏脂肪生成和糖异生中的作用,以及该蛋白在肝脏脂肪变性中的影响和功能。
细胞周期蛋白D1抑制碳水化合物反应元件结合蛋白(ChREBP),导致脂肪酸合酶(FAS)和乙酰辅酶A羧化酶(ACC)的转录减少。细胞周期蛋白D1还抑制参与肝脏脂肪生成的过氧化物酶体增殖物激活受体γ(PPARγ)。细胞周期蛋白D1抑制肝细胞核因子4α(HNF4α)和过氧化物酶体增殖物激活受体γ共激活因子1α(PGC1α),并抑制脂肪生成基因FAS和肝型丙酮酸激酶(Pklr)以及糖异生基因磷酸烯醇式丙酮酸羧激酶(PEPCK)和葡萄糖-6-磷酸酶(G6Pase)的转录。
细胞周期蛋白D1抑制肝脏中参与脂肪生成和糖异生的多种蛋白质。靶向细胞周期蛋白D1以减少非酒精性脂肪性肝病或酒精性脂肪性肝病患者的肝脏脂肪变性,可能有助于改善患者健康状况和供肝库的质量。